

Table 1. Preoperative characteristics of the study population

Variable	Group 0	Group 1	Combined	Test
	(N=143)	(N=111)	(N=254)	p
Gender (M)	73% (104)	77% (86)	75% (190)	p=0.387
Age	63.0/68.0/ 73.0	61.5/67.0/72.0	63.0/68.0/73.0	p=0.063
BMI	24.0/26.0/ 28.5	24.5/27.0/29.0	24.0/27.0/29.0	p=0.199
Diabetics	27% (38)	29% (32)	28% (70)	p=0.69
Smoke	26% (37)	32% (36)	29% (73)	p=0.252
Previous_infarction	14% (20)	14% (16)	14% (36)	p=0.923
Previous_PTCA	17% (24)	17% (19)	17% (43)	p=0.944
Previous_CABG	1% (2)	1% (1)	1% (3)	p=0.716
Peripheral_vasc	6% (8)	5% (6)	6% (14)	p=0.948
Previous_stroke	3% (4)	2% (2)	2% (6)	p=0.604
Previous_TIA	4% (6)	5% (5)	4% (11)	p=0.905
Cancer	7% (10)	7% (8)	7% (18)	p=0.947
EUROSCORE_II	1.20/1.60/ 2.05	1.10/1.70/2.15	1.20/1.60/2.10	p=0.596
Hypertension	53% (76)	45% (50)	50% (126)	p=0.2
Number of bypasses	2/3/4	2/3/4	2/3/4	p=0.974

Chol_First_control_0	156.5/180 .0/199.0	124.0/189.0/206. 0	155.0/187.0/200.0	p=0.991
Chol_3_months	141/151/1 51	97/105/118	105/137/151	p<0.001
Chol_Last_Control	121.5/135 .0/138.0	90.0/ 94.0/ 97.0	94.0/114.0/135.0	p<0.001
LDLC_First_control_0	120.5/145 .0/165.0	78.0/150.0/165.0	120.0/145.0/165.0	p=0.743
LDLC_3_months	93.0/111. 0/111.0	47.5/ 65.0/ 80.0	65.0/ 88.0/111.0	p<0.001
LDLC_Last_Control	70/ 85/100	38/ 41/ 46	42/ 65/ 88	p<0.001
HDLC_First_control_0	33/36/39	34/38/40	33/37/40	p=0.017
HDLC_3_months	38/40/41	38/40/45	38/40/43	p=0.355
HDLC_Last_Control	41.0/45.0/ 55.0	44.5/55.0/55.0	44.0/51.0/55.0	p<0.001
Tryg_First_control_0	173±16	178±17	176±16	p=0.040
Tryg_3_months	153±17	159±17		p<0.001
Tryg_Last_Control	168.0/173 .0/180.0	110.0/140.0/144. 0	140.0/155.5/175.0	p<0.001
ALT_First_control_0	32.0/37.0/ 41.0	36.0/40.0/44.0	33.0/38.5/43.0	p<0.001
ALT_3_months	41/44/54	40/45/55	41/44/55	p=0.125

ALT_Last_Control	44.00/ 45.00/ 58.00	44.00/ 55.00/ 88.00	44.00/ 54.50/ 73.75	p=0.021
Event days	29.47/ 35.50/ 47.66	13.23/ 31.50/ 44.18	22.30/ 34.50/ 45.70	p<0.001
Event	22% (32)	6% (7)	15% (39)	p<0.001

Baseline characteristics of patients treated with Evolocumab plus statin + ezetimibe (Group 1) and with statin + ezetimibe alone (Group 0). Data are expressed as percentages (absolute numbers) for categorical variables, and as median/interquartile range or mean $\pm$ standard deviation for continuous variables, as appropriate. P-values indicate the result of statistical comparisons between groups. (**BMI**: Body Mass Index; **PTCA**: Percutaneous Transluminal Coronary Angioplasty; **CABG**: Coronary Artery Bypass Grafting; **Peripheral_vasc**: Peripheral vascular disease; **TIA**: Transient Ischemic Attack; **Chol_First_control_0 / Chol_3_months / Chol_Last_Control**: Total cholesterol at baseline / after 3 months / at last follow-up; **LDLC_First_control_0 / LDLC_3_months / LDLC_Last_Control**: LDL cholesterol at the same time points; **HDLC_First_control_0 / HDLC_3_months / HDLC_Last_Control**: HDL cholesterol at the same time points; **Tryg_First_control_0 / Tryg_3_months / Tryg_Last_Control**: Triglycerides at baseline / after 3 months / at last follow-up; **ALT_First_control_0 / ALT_3_months / ALT_Last_Control**: Alanine aminotransferase at each time point.)